文献速递心脑血管急症消化、代谢与肾脏急症

V122I遗传性转甲状腺素蛋白淀粉样变基因变异与非洲或西班牙裔/拉丁裔人群心力衰竭的相关性

Association of the V122I Hereditary Transthyretin Amyloidosis Genetic Variant With Heart Failure Among Individuals of African or Hispanic/Latino Ancestry.
PubMed 文献 · JAMA · 2019-01-01
一句话结论在非洲或西班牙裔/拉丁裔人群中,TTR V122I携带者心力衰竭风险显著升高(校正OR 1.7-1.8),但携带合并心衰者仅11%被临床诊断为hATTR-CM。

该研究基于两个学术医学中心生物样本库的横断面和病例对照分析,评估非洲裔及西班牙裔/拉丁裔人群中TTR V122I变异与心力衰竭的关联及hATTR-CM诊断率。横断面队列中携带者心衰比例为44% vs 非携带者30%(校正OR 1.7,95%CI 1.2-2.4,P=.006);病例对照研究中病例携带率2.6% vs 对照1.8%(校正OR 1.8,95%CI 1.2-2.7,P=.008)。92例携带合并心衰者中仅10例(11%)被诊断为hATTR-CM,从症状出现到临床诊断的中位时间为3年。提示该变异与心衰显著相关,但临床诊断率低。

要点

  • 在非洲裔人群中,TTR V122I携带者心衰患病率44%(51/116) vs 非携带者30%(1070/3608),校正OR 1.7(95%CI 1.2-2.4,P=.006)。
  • 在非洲裔和西班牙裔/拉丁裔病例对照研究中,心衰病例携带率2.6%(36/1376) vs 对照1.8%(82/4594),校正OR 1.8(95%CI 1.2-2.7,P=.008)。
  • 92例TTR V122I携带合并心衰者中仅10例(11%)被临床诊断为hATTR-CM,从症状出现到诊断的中位时间为3年。
  • 该研究提示TTR V122I变异与心衰显著相关,但携带者中hATTR-CM的临床诊断率低。

适用人群与场景

  • 横断面队列:2008-2017年纳入Penn Medicine Biobank的50岁及以上非洲裔个体,使用1996-2017年电子健康记录数据。
  • 病例对照研究:2007-2015年纳入Mount Sinai BioMe Biobank的非洲裔和西班牙裔/拉丁裔个体,使用2007-2018年电子健康记录数据。

研究设计与关键结果

  • 横断面队列纳入3724名非洲裔个体,中位年龄64岁(IQR 57-71),男性1755名(47%),高血压2896名(78%),心肌梗死或冠脉血运重建史753名(20%);TTR V122I携带者116名(3.1%),心衰1121名(30%)。
  • 病例对照研究纳入非洲裔2307名和西班牙裔/拉丁裔3663名个体,中位年龄73岁(IQR 68-80),男性2271名(38%),高血压4709名(79%),心肌梗死或冠脉血运重建史1008名(17%);心衰病例1376例。
  • 横断面队列:TTR V122I携带者心衰51/116(44%) vs 非携带者1070/3608(30%),校正OR 1.7(95%CI 1.2-2.4,P=.006)。
  • 病例对照研究:心衰病例中TTR V122I携带36/1376(2.6%) vs 对照82/4594(1.8%),校正OR 1.8(95%CI 1.2-2.7,P=.008)。
  • 92例TTR V122I携带合并心衰者中10例(11%)被诊断为hATTR-CM,从症状出现到临床诊断的中位时间为3年。

证据类型、等级与局限

  • 证据类型:横断面分析和病例对照研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在非洲或西班牙裔/拉丁裔心衰患者中,TTR V122I携带者心衰风险显著升高,但临床诊断hATTR-CM的比例低(11%),从症状到诊断中位3年。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Hereditary transthyretin (TTR) amyloid cardiomyopathy (hATTR-CM) due to the TTR V122I variant is an autosomal-dominant disorder that causes heart failure in elderly individuals of African ancestry. The clinical associations of carrying the variant, its effect in other African ancestry populations including Hispanic/Latino individuals, and the rates of achieving a clinical diagnosis in carriers are unknown.

OBJECTIVE: To assess the association between the TTR V122I variant and heart failure and identify rates of hATTR-CM diagnosis among carriers with heart failure.

DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional analysis of carriers and noncarriers of TTR V122I of African ancestry aged 50 years or older enrolled in the Penn Medicine Biobank between 2008 and 2017 using electronic health record data from 1996 to 2017. Case-control study in participants of African and Hispanic/Latino ancestry with and without heart failure in the Mount Sinai BioMe Biobank enrolled between 2007 and 2015 using electronic health record data from 2007 to 2018.

EXPOSURES: TTR V122I carrier status.

MAIN OUTCOMES AND MEASURES: The primary outcome was prevalent heart failure. The rate of diagnosis with hATTR-CM among TTR V122I carriers with heart failure was measured.

RESULTS: The cross-sectional cohort included 3724 individuals of African ancestry with a median age of 64 years (interquartile range, 57-71); 1755 (47%) were male, 2896 (78%) had a diagnosis of hypertension, and 753 (20%) had a history of myocardial infarction or coronary revascularization. There were 116 TTR V122I carriers (3.1%); 1121 participants (30%) had heart failure. The case-control study consisted of 2307 individuals of African ancestry and 3663 Hispanic/Latino individuals; the median age was 73 years (interquartile range, 68-80), 2271 (38%) were male, 4709 (79%) had a diagnosis of hypertension, and 1008 (17%) had a history of myocardial infarction or coronary revascularization. There were 1376 cases of heart failure. TTR V122I was associated with higher rates of heart failure (cross-sectional cohort: n = 51/116 TTR V122I carriers [44%], n = 1070/3608 noncarriers [30%], adjusted odds ratio, 1.7 [95% CI, 1.2-2.4], P = .006; case-control study: n = 36/1376 heart failure cases [2.6%], n = 82/4594 controls [1.8%], adjusted odds ratio, 1.8 [95% CI, 1.2-2.7], P = .008). Ten of 92 TTR V122I carriers with heart failure (11%) were diagnosed as having hATTR-CM; the median time from onset of symptoms to clinical diagnosis was 3 years.

CONCLUSIONS AND RELEVANCE: Among individuals of African or Hispanic/Latino ancestry enrolled in 2 academic medical center-based biobanks, the TTR V122I genetic variant was significantly associated with heart failure.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Damrauer SM, Chaudhary K, Cho JH, et al. Association of the V122I Hereditary Transthyretin Amyloidosis Genetic Variant With Heart Failure Among Individuals of African or Hispanic/Latino Ancestry. JAMA. 2019. PMID: 31821430. doi:10.1001/jama.2019.17935

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。